1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63.
2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan 1;73(1):17–48. Available from: https://doi.org/10.3322/caac.21763
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
4. Kelly SP, Anderson WF, Rosenberg PS, Cook MB. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States. Eur Urol Focus. 2018;4(1):121–7.
5. Damodaran S, Lang JM, Jarrard DF. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. J Urol. 2019;201(5):876–85.
6. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer[Formula presented]. Eur Urol. 2021 Oct 16;79(2):263–82.
7. Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol. 2020;17(3):168–82.
8. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353–7.
9. Kim J, Park JS, Ham WS. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer. Investig Clin Urol. 2017;58(5):307–16.
10. Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D. Factors involved in cancer metastasis: A better understanding to “seed and soil” hypothesis. Mol Cancer. 2017;16(1):1–19.
11. Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical tria. Eur Urol. 2019;75(3):410–8.
12. Zhang Z, Wei M, Mai L, Li Y, Wu J, Huang H, et al. Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer. Front Oncol. 2020;10:549220.
13. Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer. 2019;125(3):340–52.
14. Moul J, Lee J. Rising serum PSA following local therapy for prostate cancer: diagnostic evaluation. UpToDate Inc, Waltham, MA Last Rev Novemb. 2015;222.
15. Morgan SC, Holmes OE, Craig J, Grimes S, Malone S. Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(4):1041–7. Available from: https://doi.org/10.1038/s41391-021-00339-y
16. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–66.
17. Boevé L, Hulshof M, Vis A, Zwinderman K, Twisk J, Delaere K, et al. Pd10-10 a Prospective, Randomized Controlled Trial Evaluating Overall Survival in Patients With Primary Bone Metastatic Prostate Cancer (Mpca) Receiving Either Androgen Deprivation Therapy (Adt) or Adt Combined With Concurrent Radiation Therapy To the Pro. J Urol. 2018;199(4S):e231–2.
18. Müller AC, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, et al. Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases. Strahlentherapie und Onkol. 2022;198(8):683–9. Available from: https://doi.org/10.1007/s00066-022-01961-y
19. Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019;76(1):115–24.
20. Parker CC, James ND, Brawley CD, Clarke NW, Ali A, Amos CL, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 2022 Jun 7;19(6):e1003998. Available from: https://doi.org/10.1371/journal.pmed.1003998
21. Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: Observational study of mortality outcomes. BMJ. 2014 Feb 27;348:g1502. Available from: http://www.bmj.com/content/348/bmj.g1502.abstract
22. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.
23. Antwi S, Everson TM. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis. Cancer Epidemiol. 2014;38(4):435–41.
24. Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol. 2015;194(2):378–85.
25. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34(24):2835–42.
26. Parikh RR, Byun J, Goyal S, Kim IY. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate. 2017;77(6):559–72.
27. Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, et al. Local Therapy Improves Survival in Metastatic Prostate Cancer. Eur Urol. 2017;72(1):118–24.
28. Löppenberg B, Dalela D, Karabon P, Sood A, Sammon JD, Meyer CP, et al. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. Eur Urol. 2017;72(1):14–9.
29. Galgano SJ, McDonald AM, West JT, Rais-Bahrami S. Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer. Cancers (Basel). 2022;14(14):3302.
30. Roberts MJ, Maurer T, Perera M, Eiber M, Hope TA, Ost P, et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2022;1–25.